Details of the Drug
General Information of Drug (ID: DMPMYE8)
Drug Name |
Miconazole
|
|||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Synonyms |
Dactarin; MCZ; Miconazol; Miconazolo; Miconazolum; Micozole; Minostate; Monistat; Vusion; Zimycan; Daktarin IV; Miconasil Nitrate; Miconazole nitrate salt; Miconazolo [DCIT]; Monistat IV; MJR 1762; Miconazole 3; Miconazole 3 Combination Pack; Miconazole 7 Combination Pack; Monazole 7; Monistat 1 Combination Pack; Monistat 3 Vaginal Ovules; Monistat 5 Tampon; Monistat 7 Vaginal Suppositories; R 18134; Aflorix(nitrate); Albistat(nitrate); Andergin(nitrate); Conofite(nitrate); Daktarin (TN); Femizol (TN); Femizol-M; Florid(nitrate); Lotrimin AF(nitrate); Micantin (nitrate); Micatin (TN); Miconazex (TN); Miconazol [INN-Spanish]; Miconazole-7; Miconazolum [INN-Latin]; Monista (nitrate); Monistat (TN); Monistat 3 Dual-Pak; Monistat 7 Dual-Pak; Monistat Dual-PAK; Monistat iv (TN); Monistat-Derm; Novo-Miconazole Vaginal Ovules; Epi-Monistat(nitrate); Gyno-Daktar(nitrate); Monistat-Derm (TN); R-14,889; Miconazole (JP15/USP/INN); Miconazole [USAN:BAN:INN:JAN]; Imidazole, 1-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl) methoxy)ethyl)-(9CI); Imidazole, 1-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl)methoxy)ethyl)-(9CI); (+-)-1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole; 1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole; 1-(2,4-dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl) imidazole; 1-[2,4-Dichloro-beta-([2,4-dichloro-benzyl]oxy)phenethyl]imidazole; 1-[2-(2,4-Dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]-1H-imidazole; 1-[2-(2,4-dichlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl]-1H-imidazole; 1-[2-(2,4-dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]imidazole; 1-[2-(2,4-dichlorophenyl)-2-{[(2,4-dichlorophenyl)methyl]oxy}ethyl]-1H-imidazole; 1-{2-[(2,4-dichlorobenzyl)oxy]-2-(2,4-dichlorophenyl)ethyl}-1H-imidazole
|
|||||||||||||||||||
Indication |
|
|||||||||||||||||||
Therapeutic Class |
Antifungal Agents
|
|||||||||||||||||||
Drug Type |
Small molecular drug
|
|||||||||||||||||||
Structure | ||||||||||||||||||||
3D MOL | 2D MOL | |||||||||||||||||||
#Ro5 Violations (Lipinski): 1 | Molecular Weight (mw) | 416.1 | ||||||||||||||||||
Topological Polar Surface Area (xlogp) | 5.3 | |||||||||||||||||||
Rotatable Bond Count (rotbonds) | 6 | |||||||||||||||||||
Hydrogen Bond Donor Count (hbonddonor) | 0 | |||||||||||||||||||
Hydrogen Bond Acceptor Count (hbondacc) | 2 | |||||||||||||||||||
ADMET Property |
|
|||||||||||||||||||
Chemical Identifiers |
|
|||||||||||||||||||
Cross-matching ID | ||||||||||||||||||||
Molecular Interaction Atlas of This Drug
Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Drug-Metabolizing Enzyme (DME) |
|
||||||||||||||||||||||||||
Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||
Drug-Drug Interaction (DDI) Information of This Drug
Coadministration of a Drug Treating the Disease Different from Miconazole (Comorbidity)
|
Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug
References
1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2449). | ||||
---|---|---|---|---|---|
2 | FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 076773. | ||||
3 | FDA Approved Drug Products: Oravig (miconazole) buccal tablet | ||||
4 | BDDCS applied to over 900 drugs | ||||
5 | Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds | ||||
6 | Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose | ||||
7 | Stevens RE, Konsil J, Verrill SS, Roy P, Desai PB, Upmalis DH, Cone FL: Bioavailability study of a 1200 mg miconazole nitrate vaginal ovule in healthy female adults. J Clin Pharmacol. 2002 Jan;42(1):52-60. doi: 10.1177/0091270002042001006. | ||||
8 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. | ||||
9 | Inhibition of cytochrome P450 enzymes participating in p-nitrophenol hydroxylation by drugs known as CYP2E1 inhibitors. Chem Biol Interact. 2004 Apr 15;147(3):331-40. | ||||
10 | Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65. | ||||
11 | Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47. | ||||
12 | Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75. | ||||
13 | Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9. | ||||
14 | Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772. | ||||
15 | Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98. | ||||
16 | Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6. | ||||
17 | The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76. | ||||
18 | Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. | ||||
19 | A new, broad-spectrum azole antifungal: posaconazole--mechanisms of action and resistance, spectrum of activity. Mycoses. 2006;49 Suppl 1:2-6. | ||||
20 | Clinical pharmacokinetics and pharmacodynamics of solifenacin. Clin Pharmacokinet. 2009;48(5):281-302. | ||||
21 | Antifungal agents: mechanisms of action. Trends Microbiol. 2003 Jun;11(6):272-9. | ||||
22 | Mode of action of anti-Candida drugs: focus on terconazole and other ergosterol biosynthesis inhibitors. Am J Obstet Gynecol. 1991 Oct;165(4 Pt 2):1193-9. | ||||
23 | Investigation of the role of cytochrome P450 2B4 active site residues in substrate metabolism based on crystal structures of the ligand-bound enzyme. Arch Biochem Biophys. 2006 Nov 1;455(1):61-7. | ||||
24 | Biological spectra analysis: Linking biological activity profiles to molecular structure. Proc Natl Acad Sci U S A. 2005 Jan 11;102(2):261-6. | ||||
25 | Differential azole antifungal efficacies contrasted using a Saccharomyces cerevisiae strain humanized for sterol 14 alpha-demethylase at the homolo... Antimicrob Agents Chemother. 2008 Oct;52(10):3597-603. | ||||
26 | Dutreix C, Munarini F, Lorenzo S, Roesel J, Wang Y "Investigation into CYP3A4-mediated drug-drug interactions on midostaurin in healthy volunteers." Cancer Chemother Pharmacol 72 (2013): 1223-34. [PMID: 24085261] | ||||
27 | Cerner Multum, Inc. "UK Summary of Product Characteristics.". | ||||
28 | Product Information. ORAVIG (miconazole). Strativa Pharmaceuticals, a Division of Par Pharmaceuticals, Inc., Woodcliff Lake, NJ. | ||||
29 | Heinig R, Adelmann HG, Ahr G "The effect of ketoconazole on the pharmacokinetics, pharmacodynamics and safety of nisoldipine." Eur J Clin Pharmacol 55 (1999): 57-60. [PMID: 10206086] | ||||
30 | Bolland MJ, Bagg W, Thomas MG, Lucas JA, Ticehurst R, Black PN "Cushing's syndrome due to interaction between inhaled corticosteroids and itraconazole." Ann Pharmacother 38 (2004): 46-9. [PMID: 14742792] | ||||
31 | Product Information. Synercid (dalfopristin-quinupristin) Rhone-Poulenc Rorer, Collegeville, PA. | ||||
32 | Product Information. Vraylar (cariprazine). Actavis Pharma, Inc., Parsippany, NJ. | ||||
33 | Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ. | ||||
34 | Product Information. Tykerb (lapatinib). Novartis Pharmaceuticals, East Hanover, NJ. | ||||
35 | Devenport MH, Crook D, Wynn V, Lees LJ "Metabolic effects of low-dose fluconazole in healthy female users and non-users of oral contraceptives." Br J Clin Pharmacol 27 (1989): 851-9. [PMID: 2547410] | ||||
36 | Product Information. Jevtana (cabazitaxel). sanofi-aventis , Bridgewater, NJ. | ||||
37 | Product Information. Opsumit (macitentan). Actelion Pharmaceuticals US Inc, South San Francisco, CA. | ||||
38 | Product Information. Daurismo (glasdegib). Pfizer U.S. Pharmaceuticals Group, New York, NY. | ||||
39 | Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ. | ||||
40 | Ariyaratnam S, Thakker NS, Sloan P, Thornhill MH "Potentiation of warfarin anticoagulant activity by miconazole oral gel." BMJ 314 (1997): 349. [PMID: 9040331] | ||||
41 | Product Information. Kalydeco (ivacaftor). Vertex Pharmaceuticals, Cambridge, MA. | ||||
42 | Cerner Multum, Inc. "Australian Product Information.". | ||||
43 | Product Information. Viibryd (vilazodone). Trovis Pharmaceuticals LLC, New Haven, CT. | ||||
44 | Product Information. Serzone (nefazodone). Bristol-Myers Squibb, Princeton, NJ. | ||||
45 | Product Information. Celexa (citalopram). Forest Pharmaceuticals, St. Louis, MO. | ||||
46 | Product Information. Polivy (polatuzumab vedotin). Genentech, South San Francisco, CA. | ||||
47 | Lazar JD, Wilner KD "Drug interactions with fluconazole." Rev Infect Dis 12 Suppl 3 (1990): s327-33. [PMID: 2330488] | ||||
48 | Product Information. Osphena (ospemifene). Shionogi USA Inc, Florham Park, NJ. | ||||
49 | Rolan PE, Somogyi AA, Drew MJ, et al "Phenytoin intoxication during treatment with parenteral miconazole." Br Med J (Clin Res Ed) 287 (1983): 1760. [PMID: 6416579] | ||||
50 | Product Information. VESIcare (solifenacin). GlaxoSmithKline, Research Triangle Park, NC. | ||||
51 | Product Information. Myrbetriq (mirabegron). Astellas Pharma US, Inc, Deerfield, IL. | ||||
52 | Product Information. Incivek (telaprevir). Vertex Pharmaceuticals, Cambridge, MA. | ||||
53 | Product Information. Stribild (cobicistat/elvitegravir/emtricitabine/tenofov). Gilead Sciences, Foster City, CA. | ||||
54 | Product Information. Tivicay (dolutegravir). ViiV Healthcare, Research Triangle Park, NC. | ||||
55 | Product Information. Intelence (etravirine). Ortho Biotech Inc, Bridgewater, NJ. | ||||
56 | Canadian Pharmacists Association. | ||||
57 | Product Information. Altabax (retapamulin topical). GlaxoSmithKline, Research Triangle Park, NC. | ||||
58 | Product Information. Zurampic (lesinurad). Astra-Zeneca Pharmaceuticals, Wilmington, DE. | ||||
59 | Product Information. Hetlioz (tasimelteon). Vanda Pharmaceuticals Inc, Rockville, MD. | ||||
60 | Product Information. Caplyta (lumateperone). Intra-Cellular Therapies, Inc., New York, NY. | ||||
61 | Product Information. Xalkori (crizotinib). Pfizer U.S. Pharmaceuticals Group, New York, NY. | ||||
62 | Product Information. Zykadia (ceritinib). Novartis Pharmaceuticals, East Hanover, NJ. | ||||
63 | Product Information. Lorbrena (lorlatinib). Pfizer U.S. Pharmaceuticals Group, New York, NY. | ||||
64 | Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE. | ||||
65 | Product Information. Calquence (acalabrutinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE. | ||||
66 | Product Information. Imbruvica (ibrutinib). Pharmacyclics Inc, Sunnyvale, CA. | ||||
67 | Product Information. Iclusig (ponatinib). Ariad Pharmaceuticals Inc, Cambridge, MA. | ||||
68 | Product Information. Ubrelvy (ubrogepant). Allergan Inc, Irvine, CA. | ||||
69 | Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC. | ||||
70 | Hamberg P, Woo MM, Chen LC, et al. "Effect of ketoconazole-mediated CYP3A4 inhibition on clinical pharmacokinetics of panobinostat (LBH589), an orally active histone deacetylase inhibitor." Cancer Chemother Pharmacol 68 (2011): 805-13. [PMID: 21706316] | ||||
71 | Product Information. Istodax (romidepsin). Gloucester Pharmaceuticals, Cambridge, MA. | ||||
72 | Product Information. Rozlytrek (entrectinib). Genentech, South San Francisco, CA. | ||||
73 | Product Information. Lynparza (olaparib). Astra-Zeneca Pharmaceuticals, Wilmington, DE. | ||||
74 | Product Information. Nuplazid (pimavanserin). Accelis Pharma, East Windsor, NJ. | ||||
75 | Caballero-Granado FJ, Viciana P, Cordero E, Gomez-Vera MJ, del Nozal M, Lopez-Cortes LF "Ergotism related to concurrent administration of ergotamine tartrate and ritonavir in an AIDS patient." Antimicrob Agents Chemother 41 (1997): 1207. [PMID: 9145904] | ||||
76 | Product Information. Xtandi (enzalutamide). Astellas Pharma US, Inc, Deerfield, IL. | ||||
77 | Product Information. Nubeqa (darolutamide). Bayer HealthCare Pharmaceuticals Inc., Whippany, NJ. | ||||
78 | Product Information. Rapaflo (silodosin). Watson Pharmaceuticals, Corona, CA. | ||||
79 | Product Information. Duagen (dutasteride). GlaxoSmithKline Healthcare, Pittsburgh, PA. | ||||
80 | Product Information. Letairis (ambrisentan). Gilead Sciences, Foster City, CA. | ||||
81 | Product Information. Torisel (temsirolimus). Wyeth-Ayerst Laboratories, Philadelphia, PA. | ||||
82 | Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA.". | ||||
83 | Edsbacker S, Andersson T "Pharmacokinetics of budesonide (Entocort EC) capsules for Crohn's disease." Clin Pharmacokinet 43 (2004): 803-21. [PMID: 15355126] | ||||
84 | DeVane CL, Nemeroff CB "Clinical pharmacokinetics of quetiapine - An atypical antipsychotic." Clin Pharmacokinet 40 (2001): 509-22. [PMID: 11510628] | ||||
85 | Product Information. Abilify (aripiprazole). Bristol-Myers Squibb, Princeton, NJ. | ||||
86 | Product Information. Odomzo (sonidegib). Novartis Pharmaceuticals, East Hanover, NJ. | ||||
87 | Aronson JK, Grahame-Smith DG "Clinical pharmacology: adverse drug interactions." Br Med J 282 (1981): 288-91. [PMID: 6779990] | ||||
88 | Bergmann TK, Filppula AM, Launiainen T, Nielsen F, Backman J, Brosen K "Neurotoxicity and low paclitaxel clearance associated with concomitant clopidogrel therapy in a 60 year old Caucasian woman with ovarian carcinoma." Br J Clin Pharmacol (2015):. [PMID: 26446447] | ||||
89 | Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA. | ||||
90 | Product Information. Cometriq (cabozantinib). Exelixis Inc, S San Francisco, CA. | ||||
91 | Abad S, Moachon L, Blanche P, Bavoux F, Sicard D, Salmon-Ceron D "Possible interaction between glicazide, fluconazole and sulfamethoxazole resulting in severe hypoglycaemia." Br J Clin Pharmacol 52 (2001): 456-7. [PMID: 11678792] | ||||